Science Journal

 

 

Cancer Biology

 

ISSN: 2150-1041 (print); ISSN: 2150-105X (online), doi prefix:10.7537, Quarterly

 
Volume 11 / Issue 4, Cumulated No. 44, December 25, 2021
Cover (jpg), Cover (pdf), Introduction, Contents, cbj1104

 

The following manuscripts are presented as online first for peer-review, starting from November 12, 2021. 

All comments are welcome: editor@sciencepub.net or contact with author(s) directly.

 

You can use the message in end of the article abstract to cite it.

To get Microsoft Documents: After you open the "Full Text" for each article, change the last 3 characters of the web address from .pdf to .doc (or .docx)

Welcome to send your manuscript to: sciencepub2020@gmail.com

When you submit manuscript(s), please mention that it is submitted to the Cancer Biology.

Marsland Press, 310 West 18th Street, New York, NY 10011, USA. Phone: 718-404-5362; 347-321-7172

http://www.cancerbio.net

  

CONTENTS  

No.

Titles / Authors /Abstracts

Full Text

No.

1

Retrospective analysis of management and pattern of failure in metastatic prostatic cancer at Assiut university oncology department as a model of low income city (single center experience)

 

Amin AF, Abdlftah ON, Mohammed ZS, El-Nagger MS

 

Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Assiut University, Assiut, Egypt

Email: abeeramin210@yahoo.com

 

Abstract: Aim of work: To evaluate management and pattern of failure in Metastatic Prostatic Cancer at Assuit university oncology department in period from (2009-2019) as a model of low income city and evaluate difference in disease presentation and management in comparison with high income countries. Patients and methods: Data of 111 patients with metastatic prostatic cancer presented to clinical oncology department, Assiut University Hospital during the period (2009 -2019) were reviewed as regard patients characteristic, management and pattern of failure. Results: The mean age of cases is 71 years, the most common age group is (64 to 73 years) represented in 43% of patients followed by age group (74 to 83 years) in 30% of patients. Thirty percentage had chronic diseases (most of them 20% have hypertension or diabetes mellitus or both).The most common presenting symptoms were urine retention in 25% of patients, followed by bone pain in 23% of patients. The most common pathology was prostatic adenocarcinoma and the most common Gleason score was 7 which  detected in 30% of patients, followed by G.S ≤6 (grade group 1) presented in 21% of patients, and G.S 9 or 10 (grade group 5) was in 20% of patients. As regard to Response to hormonal treatment 58% of patients the disease was stable, while disease progression occurred in 41% who were diagnosed to have CRPC by assessment of testosterone level, Median progression free survival among enrolled patients after hormonal deprivation therapy was 11 months (95%CI= 9-16). It was noticed that patients received combined hormonal therapy had significantly higher median overall survival (68 month (95%CI= 66-88) in comparison to those received single agent (65 month (95%CI=64-67)) (P< 0.001) .Twenty four  Patients who showed progression after castration received chemotherapy .Response to chemotherapy  was assessed after a follow up period of 12 months and found that; among 24 cases received chemotherapy, disease progression occurred in 92% of them, while in 8% was stationary., median progression free survival among enrolled patients after chemotherapy was 8 months (95%CI= 7-11). Elderly (70-83years) unfit Patients to ordinary treatment plan which represent 9% of newly metastatic prostate cancer and 70% of them had bone secondary considered for ADT with radiotherapy to the prostate (3600GY/6sesion/6week). Median overall survival was 24±4.65 months. Conclusion: Our study on  metastatic prostatic patients as a model of patient in developing countries has shown that Androgen deprivation therapy seems to be an effective initial treatment and had a progression free survival and overall survival  comparable to developed countries , while ADT with EBRT to the primary tumor in Elderly Patients not fit for ordinary treatment plane seems to be a good treatment option in developing countries due to its feasibility and affordable cost of our health care system , however, There was a need for novel therapeutic strategies to be available at our institute to improve patient outcomes in mCRPC.

[Amin AF, Abdlftah ON, Mohammed ZS, El-Nagger MS, Retrospective analysis of management and pattern of failure in metastatic prostatic cancer at Assiut university oncology department as a model of low income city (single center experience). Cancer Biology 2021;11(4):1-5]. ISSN: 2150-1041 (print); ISSN: 2150-105X (online). http://www.cancerbio.net  1.doi:10.7537/marscbj110421.01.

 

Keyword: Metastatic Cancer Prostate, Management, Pattern of failure

Full Text

1

2

Request to immediately stop radiotherapy and chemotherapy to treat leukemia, cancer, AIDS

 

Sun Chunwu

 

About the author: Sun Chunwu (1948-), male (Han nationality), Yangzhou City, Jiangsu Province, China, mainly engaged in natural science research

E-mail: yzscw0514@163.com; WeChat ID scw20171020

 

Abstract: Never mistake the virus for causing cancer cells to grow wildly. Long-term use of radiotherapy, chemotherapy and water infusion. Because the human body is a complex systematic project, such as more water and less water, high and low water temperature, fast and slow water flow rate, and treatment of entering the patient's body and stomach, we should pay more attention to it. Water can relieve pain, and water can aggravate illness. If you hang water for a long time, it will at least destroy the unity of the system's work and movement in your body, and will not cure the root of your illness. Such long-term treatment will be combined with the painful airflow during the treatment of patients, etc., and will be rolled by the gene centripetal vortex system, like snowballing, which will roll the chemicals and painful airflow bigger and bigger, and polymerize and copy them into a complete new cancer cell with poor quantity [that is, chemotherapy will encourage the generation of anti-treatment cancer cells].

[Sun Chunwu, Request to immediately stop radiotherapy and chemotherapy to treat leukemia, cancer, AIDS. Cancer Biology 2021;11(4):6-25]. ISSN: 2150-1041 (print); ISSN: 2150-105X (online). http://www.cancerbio.net  2.doi:10.7537/marscbj110421.02.

 

Keywords: ellipse, leukemia, cancer, AIDS, cause and prevention

Full Text

2

3

Cancer, COVID-19 and Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

 

Dr. Mark Herbert

 

World Development Institute

39 Main Street, Flushing, Queens, New York 11354, USA, ma708090@gmail.com

 

Abstract: Cancer is the general name for a group of more than 100 diseases. Although there are many kinds of cancer, all cancers start because abnormal cells grow out of control. Untreated cancers can cause serious illness and death. The body is made up of trillions of living cells. Normal body cells grow, divide, and die in an orderly fashion. During the early years of a person’s life, normal cells divide faster to allow the person to grow. After the person becomes an adult, most cells divide only to replace worn-out or dying cells or to repair injuries. Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), is the coronavirus that causes COVID-19 (coronavirus disease 2019), the respiratory illness responsible for the ongoing COVID-19 pandemic. The virus was previously referred to by its provisional name, 2019 novel coronavirus (2019-nCoV), and has also been called human coronavirus 2019 (HCoV-19or hCoV-19). First identified in the city of Wuhan, Hubei, China, the World Health Organization declared the outbreak a Public Health Emergency of International Concern on 30 January 2020, and a pandemic on 11 March 2020. SARS‑CoV‑2 is a positive-sense single-stranded RNA virus that is contagious in humans. As described by the US National Institutes of Health, it is the successor to SARS-CoV-1, the virus that caused the 2002–2004 SARS outbreak. SARS‑CoV‑2 is a virus of the species severe acute respiratory syndrome–related coronavirus (SARSr-CoV). It is believed to have zoonotic origins and has close genetic similarity to bat coronaviruses, suggesting it emerged from a bat-borne virus. Research is ongoing as to whether SARS‑CoV‑2 came directly from bats or indirectly through any intermediate hosts. The virus shows little genetic diversity, indicating that the spillover event introducing SARS‑CoV‑2 to humans is likely to have occurred in late 2019. This article introduces recent research reports as references in the related studies.

[Mark Herbert. Cancer, COVID-19 and Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 2021;11(4):26-87]. ISSN: 2150-1041 (print); ISSN: 2150-105X (online). http://www.cancerbio.net. 3. doi:10.7537/marscbj110421.03.

 

Key words: cancer; COVID-19; life; research; literature; cell

Full Text

3

4

Cancer Signs and Symptoms Research Literatures

 

Dr. Mark Herbert

 

World Development Institute

39 Main Street, Flushing, Queens, New York 11354, USA, ma708090@gmail.com

 

Abstract: Cancer is the general name for a group of more than 100 diseases. Although there are many kinds of cancer, all cancers start because abnormal cells grow out of control. Untreated cancers can cause serious illness and death. The body is made up of trillions of living cells. Normal body cells grow, divide, and die in an orderly fashion. During the early years of a person’s life, normal cells divide faster to allow the person to grow. After the person becomes an adult, most cells divide only to replace worn-out or dying cells or to repair injuries. This article introduces recent research reports as references in the related studies.

[Mark Herbert. Cancer Signs and Symptoms Research Literatures. Cancer Biology 2021;11(4):88-109]. ISSN:2150-1041(print); ISSN:2150-105X (online). http://www.cancerbio.net. 4. doi:10.7537/marscbj110421.04.

 

Key words: cancer; sign; symptom; life; research; literature; cell

Full Text

4

5

A Database of Anti-Diabetic and Anti-Cancer Plant Species from the Family Euphorbiaceae

 

Reshmina Firoz Khan, Ram P. Yadav* and Ajay Singh

 

Natural Product Laboratory, Department of Zoology, D.D.U Gorakhpur University Gorakhpur, Gorakhpur (U.P) INDIA

 

* Author to whom correspondence should be addressed: rampratapy123@gmail.com

 

Abstract: The Euphorbiaceae family has a broad distribution. This genus plants have been used in traditional medicine for a long time. Alkanes, triterpenes, phytosterols, tannins, polyphenols, and flavanoids are the key active ingredients that are thought to be responsible for various forms of operation. Members are found all over the world, and include both old and new world plants, some of which have yet to be discovered. This study provides useful and significant data for identification of different plants in Euphorbiaceae family that are extensively used as remedies against diseases and complaints such as cancer and diabetes , two most common malady to mankind.

[Reshmina Firoz Khan, Ram P. Yadav and Ajay Singh. A Database of Anti-Diabetic and Anti-Cancer Plant Species from the Family Euphorbiaceae. Cancer Biology 2021;11(4):110-115]. ISSN: 2150-1041 (print); ISSN: 2150-105X (online). http://www.cancerbio.net 5. doi:10.7537/marscbj110421.05.

 

Keywords: Euphorbiaceae, anti-cancer, anti-diabetic, phytochemicals

Full Text

5

6

Epidemiology of Female Genito-Urinary Malignancy

 

Aya Hamdy Hassan *, Samar Galal Younis, Nesreen Mohamed Sabry, Fatma Gharib Khair Allah

 

Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt

 

Abstract: Background: The incidence of endometrial cancer is higher in more developed areas of the world compared to less developed countries, indicating a possible influence of environmental factors on the incidence of this disease. The most common pathological type is endometrioid adenocarcinoma, constitute 75% to 80% of all cases. This study aimed to determine the burden of female genito-urinary malignancy, describe the Clinico-pathological pattern of all female genito-urinary tumors and find tools for screening and early diagnosis. Methods: This retrospective study carried out on 362 patients who were histopathological proved to have female genito-urinary malignancies. Patients less than 18 years old, Female patients with second primary rather than genitourinary tract malignancies were excluded from the study. Patients were categorized to patients of genital tract malignancy and of urinary tract malignancy. Patients were subjected to pathological examination, laboratory investigations including (CPC, liver and renal functions and tumour markers)and radiological investigations including (Ultrasound ,chest radiograph , CT/MRI abdomen & pelvis and bone scan). Results: Endometrial carcinoma was the most common malignancy found among all studied patients through the period of the study, 115 patients (31.8%) of all studied patients. In bladder cancer patients, 31 patients (55.4%) received 3D conformal radiotherapy, 9 patients (16.1%) received 2D palliative radiotherapy. In uterine cancer patients, 45 patients (39.1%) received 3D conformal radiotherapy, 10 patients (8.7%) received 2D radiotherapy & 2 patients (1.7%) received combined (EBRTH + brachytherapy). The differences were statistically significant (p< 0.05). Conclusions: As a part of Egyptian state policy to take care of health file in general & women’s health particularly, this study was done to register the cases of female genito-urinary malignancy & discuss the possible ways to decrease the burden of that disease and offer the best ways of treatment and early detection.

[Aya Hamdy Hassan, Samar Galal Younis, Nesreen Mohamed Sabry, Fatma Gharib Khair Allah  Epidemiology of Female Genito-Urinary Malignancy Cancer Biology 2021;11(4):116-122]. ISSN: 2150-1041 (print); ISSN: 2150-105X (online). http://www.cancerbio.net  6.doi:10.7537/marscbj110421.06.

 

Keywords: Epidemiology, Genito-urinary malignancy

Full Text

6

The manuscripts in this issue were presented as online first for peer-review starting from November 12, 2021

 All comments are welcome: editor@sciencepub.net

For back issues of the Researcher, click here.

Email: editor@sciencepub.net 

Marsland Press: http://www.sciencepub.net

 

For back issues of the Cancer Biology: click here.

doi prefix: 10.7537

Global Impact Factor: 0.324 (2012); 0.432 (2013); 0.543 (2014); 0.654 (2015)

InfoBase Index IBI Factor: 4.9 (2015); IF A2016: 3.29

Journal Index I2OR

 

 

Marsland Press: http://www.sciencepub.net

Marsland Press, 310 West 18th Street, New York, NY 10011, USA. Phone: 718-404-5362; 347-321-7172

© 2021 Marsland Press

 

 

 

 

Web counter since January 1, 2010

daily hits
Quality Inns